Tamsulosin and Solifenacin: A Dynamic Duo in BPH Management
July 2025
in “
International Journal of Health and Medicine
”
Studysummary In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings. Our plain-language summary of this paper — not a Tressless recommendation.
The study investigates the effectiveness of dual therapy with tamsulosin and solifenacin in managing lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). Involving 120 patients, the research found significant improvements in symptom severity, with mean scores dropping from 10.09 to 3.44 after treatment. Additionally, bladder capacity improved, as indicated by an increase in pre-void urine volume from 181.62 ml to 260.81 ml. However, no significant change was observed in post-void residual urine volume. These findings support the use of tamsulosin-solifenacin dual therapy in clinical protocols for BPH patients, especially those with storage-related symptoms.
